相关实验视频
Updated: Jan 26, 2026

08:02
Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
Published on: October 19, 2013
18.9K
一对罕见的病例:两例临床孤立的肺动脉动脉瘤
Donovan Cassidy-Nolan1, Claudia Cote2, Dominique de Waard3
1Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
Therapeutic advances in cardiovascular disease
|January 25, 2026
概括
肺动脉动脉瘤 (PAA) 可能是孤立的肺动脉炎的结果. 增长PAA需要进行手术修复,为管理这种罕见的血管疾病提供了洞察力.
科学领域:
- 心血管外科心血管外科
- 血管病理学血管病理学
- 类风湿病学 类风湿病学
背景情况:
- 肺动脉动脉瘤 (PAA) 是罕见的,并且可能具有严重的后果.
- 临床孤立的肺动脉炎是一种新兴的临床实体.
- PAA可能来自亚临床血管炎,类似于孤立的风炎.
研究的目的:
- 介绍一个病例系列的两个患者与临床孤立的肺动脉炎导致PAAs.
- 为了审查有关这种罕见疾病的文献.
- 在没有确定的指导方针的情况下,为PAA的管理提供指导.
主要方法:
- 两名患有大PAA的患者接受了连续胸部CT血管图.
- 进行了手术切除和主要肺动脉的合成移植.
- 进行了动脉瘤进展的术后监测.
主要成果:
- 这两种PAA的直径都超过了65毫米,并且显示间隔增长.
- 在这两种情况下,主要肺动脉的手术修复都是成功的.
- 一名患者经历了左肺动脉晚期扩张,没有计划的重新干预.
结论:
- 这些病例支持临床上孤立的肺动脉炎的存在,导致PAA.
- 这种PAA可能会恶化,需要进行手术.
- 对PAA的管理策略需要根据此类案例报告进一步开发.
相关概念视频
Aneurysm II: Clinical Manifestations and Diagnostic Studies
328
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
328
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
586
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
586
Coronary Artery Disease III: Clinical Manifestations
352
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
352
DNA Base Pairing
33.1K
Erwin Chargaff’s rules on DNA equivalence paved the way for the discovery of base pairing in DNA. Chargaff’s rules state that in a double-stranded DNA molecule,
33.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
451
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
451
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
478
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
478

